Return to top of page

The Value of Alzheimer’s Therapies


May 14, 2007
12-1:00 PM ET


National Press Club
Washington, DC


The ACT-AD coalition announces the results of a new study, showing the economic impact of delaying new treatments for Alzheimer’s disease, concluding that such treatments would be worth trillions of dollars to Americans.

  • Welcome and Introduction
    Daniel Perry, Chair, ACT-AD Coalition
    Executive Director, Alliance for Aging Research
  • Review of Study Findings
    Alzheimer’s Disease and Cost-Effectiveness Analyses: Ensuring Good Value for Money?
    John Vernon, Ph.D., Study Author, Assistant Professor, Finance Department at the University of Connecticut School of Business, Faculty Research Fellow of the National Bureau of Economic Research
  • Policy Implications of Study
    Robert Goldberg, Ph.D. Study Author, Co-founder, Vice-President and Director of Programs for the Center for Medicine in the Public Interest (CMPI)
  • A Caregiver’s Perspective on the Value of Alzheimer’s Therapies
    Meryl Comer, Alzheimer’s Association Board Member, Emmy-Award winning business and policy journalist, and Alzheimer’s caregiver and activist

To learn more about the event or the study, please visit

Living Longer and Loving It

Sign up for our monthly e-mail newsletter for the latest information on
scientific research on aging and health.

Ways to Give

There are many ways you can help accelerate the pace of scientific discoveries and their application to vastly improve the universal human experience of aging and health:

Platinum Transparency 2024 logo

The Alliance for Aging Research is a proud recipient of Candid’s Platinum Seal of Transparency.

Charity Navigator Four-Star Rating Badge

The Alliance for Aging Research is proud to be rated a 4-star charity by Charity Navigator.